PTI / Peptide Therapy Index
Clinical and preclinical peptide therapy research — indexed by study type, assessed for evidence quality. Independent. No affiliates.
TB-500 (Thymosin Beta-4) has strong preclinical evidence for tissue repair across multiple injury models, including cardiac, skin, and corneal tissue. Human clinical data is sparse and largely confined to cardiac applications. The gap between animal and human evidence is larger than commonly represented in lay discussions.
Epithalon (Epitalon) has demonstrated telomere elongation in cell culture and aged animal models, primarily through activation of telomerase. Human evidence is limited to a small number of studies from a single Russian research group, which limits the reliability of current conclusions.
BPC-157 accelerates tendon healing in animal models consistently, but human RCT data remains absent as of 2026. The existing evidence — case series and open-label reports — shows positive outcomes, but cannot be separated from placebo effect or natural recovery timelines without controlled trials.
The Peptide Therapy Index catalogues primary-source research on peptide therapies — clinical trials, preclinical studies, and evidence reviews — assessed for study type and quality. Every entry identifies whether the underlying evidence is from randomised controlled trials, animal models, case series, or review syntheses.
No commercial affiliations. No advertising. No supplements sold. Editorial standards →